{"id":"placebo-matched-to-tocilizumab","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1237022","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (tocilizumab) through comparison. It allows researchers to distinguish between the therapeutic effects of tocilizumab and effects due to placebo response or natural disease progression. The matched formulation ensures blinding and comparability between treatment arms.","oneSentence":"This is a placebo control arm matched to tocilizumab, an IL-6 receptor antagonist, and contains no active pharmaceutical ingredient.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:30.293Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06033196","phase":"PHASE2","title":"Tocilizumab in Lung Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"Lung Transplant","enrollment":350},{"nctId":"NCT04412772","phase":"PHASE3","title":"Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-06-12","conditions":"COVID-19","enrollment":20},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT04372186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2020-05-14","conditions":"COVID-19 Pneumonia","enrollment":377},{"nctId":"NCT04409262","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-06-16","conditions":"COVID-19 Pneumonia","enrollment":649},{"nctId":"NCT04320615","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-03","conditions":"COVID-19 Pneumonia","enrollment":452},{"nctId":"NCT02336048","phase":"PHASE1","title":"A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2015-06-26","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":38},{"nctId":"NCT02453256","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-20","conditions":"Systemic Sclerosis","enrollment":212},{"nctId":"NCT02573012","phase":"PHASE4","title":"Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-29","conditions":"Rheumatoid Arthritis","enrollment":314},{"nctId":"NCT01855789","phase":"PHASE3","title":"A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-07","conditions":"Rheumatoid Arthritis","enrollment":718},{"nctId":"NCT01034137","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":317},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo Matched to Tocilizumab","genericName":"Placebo Matched to Tocilizumab","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}